Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

The Food and Drug Administration bestowed Priority Review for their gene therapy. That keeps CRISPR's candidate ahead of a rival for potential first-to-market. Blockbuster status seems certain given the harsh quality of life for sickle cell patients.

Crispr Therapeutics' Exa-Cel In The Lead For Sickle Cell Disease

iBio

Pfizer

Even the most conservative investor hopes to find that one stock that can make them millions. That's why they look at the biotech sector.

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever

Crispr Therapeutics and Vertex have now had their Biologics License Application for Exa-cel accepted by the FDA - a decision date is expected in December for Sickle Cell Disease. This is the conclusion of a long development path - proving that this breakthrough CRISPR/Cas9 based drug can work, is safe, and offers a permanent cure. The market has been fairly lukewarm on Crispr stock - shares trade ~$59 when they once traded

Crispr Therapeutics: Breaking Down The Historic Exa-Cel Opportunity

CRISPR is trading for less than a third of what it did a little more than two years ago. Its lead therapy could be approved by the FDA later this year or early next year.

Where Will CRISPR Therapeutics Be in 10 Years?

ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference being held from June 12th- 15th, 2023.

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

The FDA is reviewing CRISPR Therapeutics' candidate to treat two blood disorders -- illnesses with limited treatment options today. A nod would give the company its first commercialized product.

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?

Lithium Americas Corp

QuantumScape

SoFi Technologies

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

5 Stocks to Buy With Explosive 500% Potential

Intellia Therapeutics

Intellia Therapeutics Inc. NTLA, -0.28% shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from a trial of an investigational CRISPR-based therapy for hereditary angioedema. Patients treated with a single dose of the therapy, NTLA-2002, saw durable elimination of their attacks, according to Intellia data shared Sunday at the European Academy of Allergy and Clinical Immunology conference in Hamburg, Germany.

Intellia Therapeutics stock gains on CRISPR treatment results

Eli Lilly

CRISPR Therapeutics' fortunes may soon change for the better. Eli Lily with its strong pipeline has a favorable outlook ahead.

2 Biotech Stocks That Could Help Make You a Fortune

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months

CRISPR Therapeutics (NASDAQ: CRSP ) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. The big news traders need to know about today is that both of these clinical trials met their primary endpoints.

Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?

Brookfield Renewable Partners

MercadoLibre

Brookfield Renewable has tremendous opportunities, thanks to carbon emission reduction efforts. CRISPR Therapeutics could soon have a blockbuster therapy on the market.

Wall Street Loves These 3 Growth Stocks -- Should You?

Vertex Pharmaceuticals

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress. “The updated resul.

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Pres.

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?

Editas Medicine

Invitae

An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m.

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?

Doximity

Intuitive Surgical

Intuitive Surgical, the leading robotic surgery player, keeps investing to stay on top. Doximity's strategy has delivered increasing revenue and free cash flow.

3 Top Healthcare Stocks to Buy for June

Thanks to the game-changing nature of CRISPR/Cas9, the gene-editing revolution has begun in earnest. Still, Wall Street clearly has its doubts about one of the field's founding members.

CRISPR Therapeutics: A Galaxy's Worth of Deep Value

Axsome Therapeutics

CRISPR Therapeutics is awaiting approval for a potential multi-billion product. Axsome Therapeutics has several clinical and regulatory milestones ahead.

Prediction: These 2 Stocks Could Double In the Next Year

Carnival

Demand is back for Carnival's cruises, and the company is progressing along the road to profitability. CRISPR Therapeutics may be months away from a regulatory decision -- and a potential product launch.

2 Supercharged Stocks to Buy With $100

Vertex Pharmaceuticals is one of the few gene-editing companies that is already profitable. Brookfield Renewable Partners offers exposure to diverse parts of the renewable energy landscape.

2 Top Trends to Invest $5,000 in Right Now

Teladoc

CRISPR Therapeutics may be close to launching its very first product. Teladoc Health has shifted its strategy to favor its goal of profitability.

Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health

Cathie Wood just sold quite a few shares of CRISPR Therapeutics, likely at a profit. The biotech could launch its first medicine in a year.

Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It

Regulatory marketing authorization filings for its lead drug candidate were submitted to U.S. and international bodies. Three weeks separate the U.S. filings from that of a competitor's product.

Crispr Therapeutics: Hold Until A Firmer Decision Date

Patients are currently being enrolled by CRISPR Therapeutics AG in a potentially pivotal single-arm phase 2 study using CTX-110 for the treatment of patients with large B-cell lymphoma. CTX-110 was successful in patients with LBCL in phase 1 CARBON study; patients who received CTX-110 at DL≥3 resulted in an ORR of 67% and CR rate of 41%.

News for CRISPR Therapeutics Stock (CRSP)